eIRB is Now Available
April 26, 2015 --Emory and Huron successfully upgraded Emory's eIRB system this weekend. You should notice no significant changes. In the event any technical issues or problems arise, please submit a ticket through Service Now using this link http://help.emory.edu/.
New to Emory?
If you are a new investigator at Emory, we encourage you to make an appointment with the IRB to take stock of your studies and prepare a plan for a smooth transfer of your research projects. Please visit the About page for general contact information and a list of IRB staff, or send us an email at email@example.com.
What's New at the IRB?
Many IRB Staff Will Be Out of the Office on 4/23/2015
Several IRB staff members will attend an OHRP conference on Thursday, April 23. If you need assistance on that day, please call the main number at 404-712-0720 and plan accordingly.
Webinar on Continuing Review Considerations
On April 9 at 12:00 pm (Noon), the Emory IRB will deliver a concise webinar to highlight what sort of information should be included at continuing reviews, such as reports, summaries, and other documentation. The presentation will be about 20-30 minutes long with a live question and answer session afterwards. A link to the live webinar, as well as recordings of each webinar, are available on the Webinars page.
Condensed Meeting Schedules Nov-Jan
Please see our adjusted holiday meeting schedule. The IRB will have condensed meeting schedules during the months of November, December, and January. If you have a study that will be expiring during this time period, we highly recommend that you submit a Continuing Review early to ensure ample time for our evaluation and approval. If you have any questions or concerns, please feel free to contact us.
New Guidance for Drug/Device Studies
The IRB has created new guidance documents for investigators working with FDA regulated products. These documents, which may be found on the New Submission Guidance page, cover in vitro diagnostic devices, Emory sponsor-investigators, and expanded access use of drugs and devices.